Indeed, it is well established that NF-κB activation and pathway have a key role in mediating cancer drug resistance, the survival, proliferation, migration and angiogenesis of several tumor cells [48,49,50,51], and targeting of NF-κB pathway may play a central role in reversing resistance to chemotherapeutics and enhancing chemosensitization of cancer cells [52,53,54]. The gene discussed is NFKB1; the disease is neoplasm.